Balanitis xerotica obliterans
ICD-10 N48.0 · ICD-11 EB60.1

Treatment of Balanitis Xerotica Obliterans with Phimosis in Boys Under 18

When balanitis xerotica obliterans (BXO) occurs in a child under 18 alongside phimosis, the clinical picture calls for a specific, age-appropriate approach. Both the presence of phimosis and the patient's age are key factors that shape treatment selection in this scenario.

This protocol addresses pediatric patients — under 18 years of age — in whom BXO presents together with phimosis. Phimosis (restricted foreskin retraction) in this context is both a defining feature of the presentation and a primary target of treatment.

First-line management in this setting involves a course of topical corticosteroid therapy applied to the affected area. The complete regimen — including the specific agent, application details, and the pathway if initial therapy does not achieve the expected result — is detailed in the full protocol.

The primary clinical goal is:

Resolution of penile phimosis
Instant Access to Structured Evidence-Based Regimens

References

DOI: 10.1111/ijd.14236

Daily use of potent topical corticosteroids (TCS) is the recommended first-line therapy for BXO in adult males and boys, for example, one fingertip unit of 0.05% clobetasol propionate ointment, as per the British Association of Dermatology (BAD) guidelines.

In boys, the same guidelines suggest that those with phimosis be referred to a pediatric urologist for circumcision following 1–3 months of failed TCS.

View source ↗